Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Inflazyme, Aventis deal

AVE's Aventis Pharma AG unit bought C$5.8 million (US$4 million) of IZP convertible

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE